PBMs: The 'shadow' players in the drug pricing skirmish?
20 May 2016
With the U.S. drug pricing system as transparent as the darkest shadows, pharmacy benefit managers (PBMs) have stayed out of the political spotlight on the escalating cost of many drugs.
How Big Pharma Uses Charity Programs to Cover for Drug Price Hikes
20 May 2016
In August 2015, Turing Pharmaceuticals and its then-chief executive, Martin Shkreli, purchased a drug called Daraprim and immediately raised its price more than 5,000 percent. Within days, Turing contacted Patient Services Inc., or PSI, a charity that helps people meet the insurance copayments on costly drugs. Turing wanted PSI to create a fund for patients with toxoplasmosis, a parasitic infection that is most often treated with Daraprim.
Industry hits back at idea of pharma levy in superbug fight
20 May 2016
The drug industry hit back on Thursday at a proposal to charge firms a levy to help fund development of new antibiotics and said the idea, set out in a high-level UK review of drug-resistant superbugs, would "undermine goodwill".
Real-time Data Tracking in the Clinical Trial Supply Chain
20 May 2016
It’s 2016: airplanes, ships, trains and even cars send a constant mass of sensor data to central servers. Almost 50% of the world’s population uses a smartphone. We communicate with these mobile computers continually, globally.
Registries and the Future of Medicine
20 May 2016
Payers, providers, patients and pharmaceutical companies all want to understand the value of specific treatments – and patient registries can help them do that. These online data platforms give patients and providers a single place to record information about diagnosis, condition and treatment experience.
Biopharma Supports Nearly 4.5 Million US Jobs, Says Report
19 May 2016
The biopharma industry supported nearly 854,000 direct jobs and another 3.5 million jobs and more than $1.2 trillion in economic output in the United States in 2014, according to new research prepared for the Pharmaceutical Research and Manufacturers of America (PhRMA).
19 May 2016
The European Medicines Agency (EMA) published its 2015 annual report on May 17, 2016. The report provides information on the agency’s market authorization approvals for the year, gives an update on the agency’s projects, and features interviews with industry representatives on topics such as data requirements and immunotherapies.
J&J commits $740M for its second cancer R&D pact with MacroGenics
19 May 2016
Whatever Johnson & Johnson ($JNJ) learned about MacroGenics’ off-the-shelf approach to stirring a T cell attack against cancer since inking their first partnership deal 17 months ago seems to have only whetted the pharma giant’s appetite for more.
Large-scale HIV vaccine trial to launch in South Africa
19 May 2016
An early-stage HIV vaccine clinical trial in South Africa has determined that an investigational vaccine regimen is safe and generates comparable immune responses to those reported in a landmark 2009 study showing that a vaccine can protect people from HIV infection.
The Remarkable Rebirth of Cancer Immunotherapy
18 May 2016
There’s reason for new hope in the ongoing battle against cancer. From standing-room-only presentations of provocative data at cancer conferences, to landmark publications and new drugs approvals, the signs are multiple and clear. Harnessing the immune system as an anti-cancer therapy--a strategy that has yet to fully deliver on its promise-- is now the most exciting area of oncology drug development.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Putin has stated that Russia will support Africa in the struggle against epidemics
19 April 2024
The Russian government has expanded the list of vital and essential drugs
19 April 2024
Achieving FAIR bacterial identification
18 April 2024
Unique testing regimen could prevent nuclease contamination
18 April 2024